Interpace Biosciences reports Q3 2026 revenue range
- Q3 2026 revenue expected between $10.1M and $10.4M
- QoQ growth of 11% to 14% compared to Q2 2026
- YoY growth of 15% to 18% compared to Q3 2025
Every EDGAR filing for INTERPACE BIOSCIENCES, INC. (IDXGD), newest first, with AI summaries and stories.
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Thomas W. Burnell, insider filing for IDXG
Thomas W. Burnell, reporting
1315 Capital II, L.P., insider filing for IDXG
1315 Capital II, L.P., reporting
Ampersand 2018 Limited Partnership, insider filing for IDXG
Ampersand 2018 Limited Partnership, reporting